Protalix BioTherapeutics Inc (PLX)
1.40
-0.01
(-0.71%)
USD |
NYAM |
Nov 15, 16:00
1.39
-0.01
(-0.71%)
After-Hours: 20:00
Protalix BioTherapeutics Research and Development Expense (TTM): 12.62M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 12.62M |
| March 31, 2024 | 14.13M |
| December 31, 2023 | 17.09M |
| September 30, 2023 | 19.61M |
| June 30, 2023 | 23.32M |
| March 31, 2023 | 26.43M |
| December 31, 2022 | 29.35M |
| September 30, 2022 | 31.37M |
| June 30, 2022 | 31.27M |
| March 31, 2022 | 31.38M |
| December 31, 2021 | 29.73M |
| September 30, 2021 | 33.05M |
| June 30, 2021 | 33.45M |
| March 31, 2021 | 34.95M |
| December 31, 2020 | 38.17M |
| September 30, 2020 | 36.81M |
| June 30, 2020 | 39.12M |
| March 31, 2020 | 43.26M |
| December 31, 2019 | 44.62M |
| September 30, 2019 | 44.60M |
| June 30, 2019 | 44.67M |
| March 31, 2019 | 38.58M |
| December 31, 2018 | 33.33M |
| September 30, 2018 | 32.74M |
| June 30, 2018 | 29.06M |
| Date | Value |
|---|---|
| March 31, 2018 | 30.65M |
| December 31, 2017 | 28.83M |
| September 30, 2017 | 25.55M |
| June 30, 2017 | 24.22M |
| March 31, 2017 | 23.21M |
| December 31, 2016 | 24.61M |
| September 30, 2016 | 25.31M |
| June 30, 2016 | 24.20M |
| March 31, 2016 | 21.08M |
| December 31, 2015 | 20.02M |
| September 30, 2015 | 18.71M |
| June 30, 2015 | 20.86M |
| March 31, 2015 | 21.13M |
| December 31, 2014 | 22.22M |
| September 30, 2014 | 25.73M |
| June 30, 2014 | 25.26M |
| March 31, 2014 | 26.76M |
| December 31, 2013 | 26.01M |
| September 30, 2013 | 24.04M |
| June 30, 2013 | 24.77M |
| March 31, 2013 | 27.17M |
| December 31, 2012 | 28.69M |
| September 30, 2012 | 29.60M |
| June 30, 2012 | 31.15M |
| March 31, 2012 | 29.62M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
12.62M
Minimum
Jun 2024
44.62M
Maximum
Dec 2019
29.99M
Average
31.37M
Median
Sep 2022
Research and Development Expense (TTM) Benchmarks
| Accuray Inc | 47.84M |
| Aethlon Medical Inc | -- |
| AIM ImmunoTech Inc | 9.03M |
| Perspective Therapeutics Inc | 28.53M |
| Armata Pharmaceuticals Inc | 32.40M |